This Program for a Common Problem May Be Vertex Pharmaceuticals' Ticket to a New Wave of Billion-Dollar Revenues
Vertex Pharmaceuticals (NASDAQ: VRTX) generates billions of dollars in annual revenues from its treatments for the rare disease cystic fibrosis. And Vertex should continue to dominate in cystic fibrosis and bring in blockbuster revenue well into the future thanks to its life-saving treatments. But the big biotech company may soon also make headlines with a treatment for a far more common problem -- and this could result in a whole new massive revenue stream.
We've all suffered from this problem at one time or another. I'm talking about pain. The problem is that treatment options today are limited to a few over-the-counter options or prescription opioids. Vertex's candidate, VX-548, is a non-opioid option that the company thinks could take the market by storm.
Image source: Getty Images.
Source Fool.com
Vertex Pharmaceuticals Inc. Aktie
Die Aktie ist durchaus ein Favorit unsere Community mit 57 Buy-Einschätzungen und 2 Sell-Einschätzungen.
Ein leichtes Potenzial nach oben für Vertex Pharmaceuticals Inc. mit einem Kursziel von 440 € gegenüber dem aktuellen Kurs von 432.65 €.